Recent Posts

1. 

   Allergy Territory Account Specialist

   Remibrutinib is also in development for food allergy and hidradenitis suppurativa due to the Q1 investor presentation.

   Novartis

   anonymous

   Apr 23, 2024 at 10:00 PM

2. 

   BRAD clueless

   Things are so much different since the “reorg”, and not in a good way. Leadership totally disconnected, losing good reps daily. Seems like everyone sees it but them. Hopefully “they” figure it out.

   Bausch & Lomb

   anonymous

   Apr 23, 2024 at 9:57 PM

3. 

   WHC reorganization is here!

   Funny you say that. Kerendia is quite literally one of a small handful of drugs that are keeping the entire company afloat. Get back to your home study materials.

   Bayer

   anonymous

   Apr 23, 2024 at 9:56 PM

4. 

   FOR SALE

   I hear you, Karen. No one wants to debate someone with your intellectual prowess.

   Esperion

   anonymous

   Apr 23, 2024 at 9:54 PM

5. 

   Channel your inner worthlessness

   This fucking company

   Blue Earth Diagnostics

   anonymous

   Apr 23, 2024 at 9:53 PM

6. 

   Vertex Pharma Obtains Exclusive License To TreeFrog's Cell Manufacturing Technology,...

   via Vertex Pharmaceuticals Inc. (VRTX) announced Tuesday that it has obtained an exclusive license from TreeFrog Therapeutics, a French-based biotech company, to its proprietary cell manufacturing technology, C-Stem, to optimize production of...

   Pharma/Biotech Companies - In the News

   cafead

   Apr 23, 2024 at 9:52 PM

7. 

   Alzheimer's drug adoption in US slowed by doctors' skepticism

   via Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi is facing an unexpected hurdle to widespread use: an entrenched belief among some doctors that treating the...

   Pharma/Biotech Companies - In the News

   cafead

   Apr 23, 2024 at 9:52 PM

8. + Show More